Business Milestones

Company History

Cumberland Pharmaceuticals and its leadership have been honored with a variety of awards recognizing the company’s entrepreneurial spirit and business success.


Cumberland Pharmaceuticals Releases Inaugural Report On It's Environmental, Social, and Governance (ESG) Activities.


Received FDA Orphan Drug Grant Funding and initiated clinical program to study ifetroban in patients with Duchenne Muscular Dystrophy.

Received FDA approval for RediTrex® line of injectable methotrexate products.

Obtained FDA approval for Next Generation Caldolor® product featuring a new patented formulation and improved packaging.

Completed a company-wide strategic review of products, partners, and organization.


In January 2018, Cumberland Pharmaceuticals launches the Cumberland Pharma Foundation to organize and facilitate its ongoing philanthropic endeavors to various non-for-profit organizations whose activites align with Cumberland’s mission.

A new published study demonstrates the superiority of Caldolor® over IV acetaminophen in reduction of post-surgical pain and opioid use. Data also supports the preemptive use of Caldolor® in reducing pain and reliance on opioids post-surgery.

In November 2018, Cumberland enters into an agreement to acquire Vibativ® (telavancin) for injection.


In January 2017, the U.S. Court of Appeals affirms Cumberland Pharmaceuticals’ victory in patent litigation case associated with its Acetadote® product.

Decmber 2017, Nashville Business Journal features Cumberland as the fastest growing Nashville health care company of 2017.


Cumberland announces new development program to develop Vasculan® oral capsule for the treatment of systemic sclerosis.


Cumberland announces the approval of Caldolor® (ibuprofen) Injection for pediatric patients six months of age and older.

Cumberland expands pipeline with Boxaban® (ifetroban) oral capsule for the treatment of asprin-exacerbated respiratory disease.


Cumberland announces fifth commercial product Vaprisol® for the treatment of hyponatremia.


Cumberland announces fourth commercial product Omeclamox® -Pax for the treatment of H.pylori.


Cumberland is named to Modern Healthcare’s Inaugural Healthcare’s Hottest List honoring healthcare’s 40 fastest growing healthcare companies.

Cumberland Pharmaceuticals is named as a finalist in the Nashville Business Journal’s “Best in Business” competition.


Cumberland Pharmaceuticals named to as one of the Fastest Growing Companies in North America on Deloitte's 2011 Technology Fast 500™ list for the second consecutive year.

In November 2011, Cumberland reached an agreement to acquire the FDA registration and trademark for Kristalose®.

Cumberland Pharmaceuticals launches next generation Acetadote® product.


Cumberland CEO A.J. Kazimi is named a finalist for Ernst & Young’s Entrepreneur Of The Year® award in Alabama/Georgia/Tennessee for the second consecutive year.

Cumberland Pharmaceuticals is once again recognized as a finalist in the Nashville Business Journal’s Best in Business competition.


Cumberland launches Caldolor® the first injectable treatment for pain and fever approved in the U.S.

Cumberland completes Initial Public Offering  and share listing on NASDAQ exchange.


Cumberland is named to the Inc. 500 list of America’s fastest growing private companies.

Cumberland launches co-promotion of Kristalose® the only prescription laxative product available in a powder formulation for the treatment of acute and chronic constipation.


Cumberland is named to Business Tennessee magazine’s Fast 50 list for a second year in a row.

Cumberland is honored with a Music City Future 50 Award, which recognizes the region’s most successful private companies.


Cumberland is recognized as one of Business Tennessee magazine’s fastest growing 50 private companies.

Cumberland Pharmaceuticals launches their first FDA approved product Acetadote® for the treatment for Acetaminophen overdose.